MDB 401 B
Alternative Names: Attenuated Salmonella typhimurium containing human IL-2; MDB401B; Salmonella-IL2; Saltikva®Latest Information Update: 29 Nov 2023
At a glance
- Originator Salspera; Sunshine Lake Pharma
- Developer Salspera
- Class Antineoplastics; Bacteria; Gene therapies; Immunotherapies
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pancreatic cancer
- Phase I Gastrointestinal cancer; Solid tumours
Most Recent Events
- 05 Jan 2023 Efficacy and adverse events data from a phase II trial in Pancreatic cancer released by Salspera
- 05 Jan 2023 Salspera plans a phase III trial for Pancreatic cancer at unknown location
- 26 Dec 2022 Phase II development for Pancreatic cancer is still ongoing in Canada (Salspera pipeline, December 2022) (NCT04589234)